{"id":135177,"date":"2026-09-23T15:27:11","date_gmt":"2026-09-23T15:27:11","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/135177\/"},"modified":"2026-09-23T15:27:11","modified_gmt":"2026-09-23T15:27:11","slug":"novartis-locks-in-preclinical-rlt-under-900m-boomray-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/135177\/","title":{"rendered":"Novartis locks in preclinical RLT under $900M Boomray deal"},"content":{"rendered":"<p>Cancer<\/p>\n<p>Novartis Pharma AG inked a potential $900 million deal to gain exclusive global rights to a preclinical radioligand therapy (RLT) from Boomray Pharmaceuticals Co. Ltd., as the Swiss big pharma staves off increasing competition around Lutathera (lutetium [Lu 177] oxodotreotide).<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/520-bioworld-science\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld Science<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/214-deals-and-m-a\" rel=\"nofollow noopener\" target=\"_blank\">Deals and M&amp;A<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/325-diagnostics\" rel=\"nofollow noopener\" target=\"_blank\">Diagnostics<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/239-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Cancer<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/393-asia-pacific\" rel=\"nofollow noopener\" target=\"_blank\">Asia-Pacific<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/395-china\" rel=\"nofollow noopener\" target=\"_blank\">China<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Cancer Novartis Pharma AG inked a potential $900 million deal to gain exclusive global rights to a preclinical&hellip;\n","protected":false},"author":2,"featured_media":135178,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[941,8086,15287,49362,65259,65260,2112,351,8568,1176,197,65261,44134,206,1078,31818,4117,8514,65262,42439],"class_list":["post-135177","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-asia-pacific","tag-bioworld","tag-bioworld-asia","tag-bioworld-science","tag-boomray-pharmaceuticals-co-ltd","tag-brp-0x0","tag-cancer","tag-china","tag-deals-and-ma","tag-diagnostics","tag-europe","tag-gastroenteropancreatic-neuroendocrine-tumors","tag-lutathera","tag-novartis","tag-novartis-ag","tag-pluvicto","tag-prostate-cancer","tag-radioligand-therapy","tag-radiopharmaceutical","tag-solid-tumors"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117321062548876999","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135177","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=135177"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/135177\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/135178"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=135177"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=135177"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=135177"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}